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Background: The Abelson tyrosine kinase (c-Abl) inhibitor STI571 (Glivec®) has been shown to effectively inhibit
colorectal cancer cell migration and invasion. The c-Abl substrate abelson interactor 1 (Abi1) is a key regulator of actin
reorganization and upregulated in colorectal carcinoma. The specific role of Abi1 in relation to extracellular matrix
degradation and effects of targeting Abi1 phosphorylation have not yet been examined. Here, we investigated
the role of Abi1 in relation to invasive properties in colorectal cancer.
Methods and results: In 56 primary human colorectal carcinoma samples, we found overexpression of Abi1 in
39% at the invasive edge of the tumour, associated with an infiltrative phenotype and high-grade tumour cell
budding (p = 0.001). To explore the role of Abi1 in vitro, we employed the Abi1 expressing and KRAS-mutated
CHD1 model and performed matrix degradation assays that showed Abi1 localization at specific sites of matrix
degradation. Moreover, quantification of matrix dissolution demonstrated suppression after RNAi knockdown of
Abi1 by 95% (p = 0.001). Importantly, treatment with STI571 did abolish Abi1 Y435-phosphorylation, suppressed
the matrix dissolution, decreased fibronectin attachment, and suppressed cell invasion through reconstituted
extracellular matrix.
Conclusion: Our data indicate that phosphorylated Abi1 contributes to the invasive properties of colorectal
cancer.
Keywords: Abelson interactor 1 (Abi1), Colorectal carcinoma, Extracellular matrix (ECM), Invasion, MetastasisBackground
Colorectal carcinoma (CRC) is the second leading cause
of death from cancer in the western world in both women
and men [1]. Patient prognosis is in most cases deter-
mined by the ability of tumour cells to invade into sur-
rounding tissue, gain access to blood vessels and form
distant metastases after dissemination with the blood
stream. Accordingly, a dissociative tumour growth pattern
with single-cell infiltration and high-grade tumour cell* Correspondence: konrad@steinestel.com
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unless otherwise stated.budding has been shown to be associated with poor prog-
nosis in colorectal cancer [2,3].
Tumour cells facilitate extracellular matrix (ECM)
degradation and invasion through the formation of
specialized cytoplasmic protrusions, so-called invado-
podia [4]. These consist of parallel actin bundles on
the basis of a branched actin meshwork and are enriched
in proteins that are involved in actin remodelling, includ-
ing Cortactin, formins of the Diaphanous family and class
I nucleation-promoting factors (NPFs) such as WASP or
N-WASP [5]. Actin reorganization is tightly regulated;
actin-related proteins (such as Arp2/3) that facilitate actin
branching underlie the control of signalling cascades
modulating the activity of NPFs and small GTPases [6].ral Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
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branched actin filaments give rise to broad-based lamelli-
podia that are a prerequisite for cellular migration [5,6].
Abelson interactor 1 (Abi1) is a 65kD-substrate of the
eponymous Abelson non-receptor tyrosine kinase (c-Abl).
The protein is almost ubiquitously expressed with a main
focus in the central nervous system [7]. It has been shown
that Abi1 plays a central role in synaptic maturation, since
knockdown experiments in cultured rat hippocampal neu-
rons led to an immature, filopodia-like synaptic phenotype
[8]. In a previous study, we could show that heteroge-
neous nuclear ribonucleoprotein K, a 65kD protein that
has the ability to act as a translational regulator via bind-
ing to mRNA transcripts, interacts with Abi1 in hippo-
campal neurons and exerts a similar effect on synaptic
maturation [9]. The role of Abi1 in cytoskeletal dynamics
during lamellipodia formation has been linked to its ability
to join the WAVE multiprotein complex including Abi1,
Nap1, HSPC300 and Sra/PIR121 [10,11]; the active com-
plex brings bound Arp2/3 and actin monomers into close
proximity, thus enhancing actin polymerization [12]. Ac-
cordingly, Abi1-deficient mouse embryos show malforma-
tions in the developing heart and brain and die around
embryonic day 11; furthermore, they show decreased in-
tegrity and function of the WAVE complex [13]. Interest-
ingly, Abi1 has also been shown to interact with the PI3-
Kinase, enhancing cytoskeletal reorganization processes in
support of cellular migration via activation of Rac activity
[14,15]. In invading breast cancer cells, Abi1 is required
for invadopodia formation and matrix-metalloproteinase
9 secretion [16]. Some effects of Abi1 on cytoskeletal
reorganization are dependent on phosphorylation of
the protein, and interestingly, application of the Abel-
son tyrosine kinase inhibitor STI571 (Glivec®) has been
previously found to effectively suppress colorectal cancer
cell invasion as well as metalloproteinase-dependent matrix
degradation by breast cancer cells [17-19]. Significant anti-
invasive effects of STI571 on colon cancer cells have been
observed upon application of subtoxic concentrations of
the drug in several reports, while the underlying mecha-
nisms remain elusive [18,20,21]. In a previous study, we
could show that Abi1 is strongly expressed in colorectal
adenomas and carcinomas compared to healthy mucosa,
and KRAS-mutated hyperplastic polyps show overexpres-
sion of the protein compared to their wild-type or BRAF-
mutated counterparts [22]. Accordingly, overexpression of
interaction partners of Abi1 (hnRNP K, N-WASP and
WAVE2) has also been previously reported in colorec-
tal carcinoma and CRC metastasis [23-26]. Given the role
of Abi1 in actin dynamics, the goal of this study was to in-
vestigate its function in extracellular matrix degradation and
invasion by CRC cells. Furthermore, we examined the effect
of STI571 on Abi1 phosphorylation, metalloproteinase secre-
tion, ECM degradation and colorectal cancer cell invasion.Results
Abi1 mRNA expression patterns in gastrointestinal
adenocarcinomas
Quantitative Abi1 gene expression data for oesophageal
(n = 13), gastric (n = 21), small intestinal (n = 6) and
colorectal (n = 505) adenocarcinomas obtained from the
GeneSapiens transcriptomics database showed compar-
able expression levels between tumour entities (Figure 1A).
Median relative expression levels ranged from about 680
(small intestine adenocarcinoma) to 840 (colorectal car-
cinoma) arbitrary units.Clinic-pathologic sample characteristics
56 colorectal carcinoma surgical specimens were included
in the study. All UICC stages, tumour localizations and
histopathologic differentiations were represented among
the sample cohort (Table 1). Lymph vessel infiltration was
present in 19 cases (34%), while blood vessel infiltration
was present in 10 tumours (18%). 36% of tumours showed
an infiltrating growth pattern; 16 tumours (29%) displayed
high-grade tumour cell budding at the leading edge. Stat-
istical analysis (Fisher’s exact test) revealed a significant
correlation between infiltrating growth pattern and high-
grade tumour cell budding (p < 0.001) and confirmed the
association between both infiltrating tumour growth and
high-grade tumour cell budding and the presence of
lymph or blood vessel invasion by the tumour (L1/V1,
p = 0.019 and p = 0.011). 7 tumours (13%) showed loss
of mismatch repair protein expression that was signifi-
cantly associated with expanding, but not infiltrating
growth pattern (p = 0.042). Activating KRAS or BRAF
mutations were present in 42% and 4% of samples,
respectively.Expression of Abi1 at the invasion front of colorectal
cancer
Immunohistochemistry for Abi1 showed strong expres-
sion of the protein at the invasive margin of infiltrating,
but not expanding CRC (Figure 1B I-III); statistical ana-
lysis revealed significant higher Abi1 staining score at
the leading edge of the tumours compared to tumour
centre (Figure 1C I; p < 0.001). There was significant
overexpression of the protein in tumours displaying an
infiltrating growth pattern and high-grade tumour cell
budding compared to expanding tumours with a “pushing
border” configuration (Figure 1B and 1C II, p < 0.001).
Abi1 expression correlated with lymph or blood ves-
sel invasion by the tumour (L1V1 status, Figure 1C
III; p = 0.027). Immunofluorescence staining and quantifi-
cation of staining intensities with an antibody against a
phosphorylated isoform of Abi1 (pY435) showed strong
nuclear and cytoplasmic positivity in dissociated tumor
cells at the invasion front, but only weak staining signals
Figure 1 Abi1 expression analyses. A, in silico gene expression analysis using the GeneSapiens database [31] shows no significant differences
in Abi1 gene expression among adenocarcinomas of gastrointestinal origin. B, representative microphotographs of Abi1 immunohistochemistry
at the invasive margin of expanding (I) and infiltrating (II) CRC. Tumour cell budding in (II) is indicated by arrows. Greater magnification (III) shows
strong Abi1 expression in cytoplasm and podia-like cellular protrusions (arrows). Immunofluorescence staining for phosphorylated Abi1 (p435)
shows strong positivity in dissociating tumour cells at the invasive margin (IV). C, statistical evaluation of Abi1 IHC staining scores shows significant
higher expression scores at the leading edge compared to tumour centre (I) as well as in tumours with infiltrating growth and high-grade tumour cell
budding compared to tumours with expanding growth and low-grade budding (II). Moreover, Abi1 expression score is significantly associated with
lymph and/or blood vessel infiltration by the tumour (III). Quantification of staining intensities (IV) shows stronger cytoplasmic as well as nuclear positivity
for phosphorylated Abi1 (pY435) at the invasive margin compared to the tumour centre. IHC, immunohistochemistry; exp, expanding growth; inf, infiltrating
growth; 0–9, 10: intensity of tumour cell budding in an x250 visual field. Scale bars as indicated. *p < 0.05; ***p < 0.001.
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Table 1 Clinic-pathologic sample characteristics
No. of patients 56
No. of samples 56 (100%)
























MMR proteins expressed 49 (87%)
Loss of MLH1 + PMS2 6 (11%)
Loss of PMS2 1 (2%)
KRAS status (n = 55)
KRAS wild-type 32 (58%)
KRAS G12D 9 (16%)
KRAS G12V 7 (13%)
KRAS G12C 1 (2%)
KRAS G12S 1 (2%)
KRAS G13D 5 (9%)
BRAF status
BRAF wild-type 54 (96%)
BRAF V600E 2 (4%)
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and Figure 1C IV).
Expression and phosphorylation of Abi1 in CHD1 cells
CHD1 colorectal carcinoma cells are positive for Abi1,
hnRNP K and Laminin5γ2 in Western immunoblotting
(Figure 2A and Additional file 1: Figure S1A). The anti-
body against Laminin5 detected two bands migrating at
100kD (L5γ2′) and 85kD (L5γ2x), indicating cleavage of
the protein [27]; E-cadherin was not expressed at a de-
tectable level in CHD1 whole cell lysate. These findings
could be confirmed in IF microscopy (Additional file 1:
Figure S1B). Further immunofluorescence analyses showed
localization of Cortactin and Abi1 to the outer rim of
lamellipodia-like cellular protrusions (Figure 2B I and II).
Immunofluorescence staining with an antibody against
Y435-phosphorylated Abi1 showed strand-like positivity
along the growth axis of cellular protrusions (Figure 2B
III); treatment with 10 μM of the Abl tyrosine kinase in-
hibitor STI571 markedly reduced Abi1 and pAbi1 positiv-
ity in peripheral cellular compartments with remaining
central (perinuclear) positivity for Abi1.
Fibronectin cell adhesion assay
When seeded onto fibronectin-coated coverslips, CHD1
cells showed outgrowth of broad-based lamellipodia with
peripheral, strand-like positivity for phosphorylated Abi1
(Figure 2C I and II). 10 μM STI571 significantly im-
paired lamellipodia formation and cellular adhesion on
fibronectin (Figure 2C III-V, p < 0.001).
Gelatine-based ECM degradation assay
When CHD1-cells were seeded out on fluorescent gelatine-
coated coverslips, Cortactin and Abi1 localized to periph-
eral foci of matrix degradation (Figure 3A I and II). This
was confirmed in 3D surface reconstruction, where rim-
like Abi1 positivity in the cell periphery co-localized with
sites of matrix cleavage (Figure 3A III). Application of
10 μM STI571 led to a complete arrest in matrix degrad-
ation (Figure 3A IV).
Effect of tyrosine kinase inhibition and Abi1 RNAi
knockdown on ECM degradation
To further investigate the role of (phosphorylated) Abi1
in ECM degradation, CHD1 cells were seeded out on
fluorescent gelatine-coated coverslips and either treated
with 10 μM STI571/DMSO or transfected with RNAi
targeting Abi1/vector control; after 24 h, degradation
area was measured and degradation coefficients were
calculated (see “Materials and methods” section for de-
tails). Statistical analysis revealed that 10 μM STI571 as
well as Abi1 RNAi knockdown significantly reduced the
ability of CHD1 cells to lyse extracellular matrix compared
Figure 2 Abi1 expression and subcellular localization in CHD1 colorectal carcinoma cells. A, western immunoblotting of CHD1 whole cell
lysate shows expression of Abi1 and hnRNP K as well as a 100/85 kD double-band for Laminin5, but no detectable levels of E-Cadherin. B, IF microscopy
shows peripheral, rim-like distribution of Cortactin (I) and Abi1 (II). Signals for both Abi1 and Y435-phosphorylated Abi1 in the cell periphery, but not in the
perinuclear region, are extinct after treatment with 10 μM STI571 (III). C, fibronectin adhesion assay shows cellular attachment with lamellipodial protrusions
(I) and peripheral positivity for Y435-phosphorylated Abi1 (II) under control conditions, but only few attached cells (III) with condensed actin and negativity
for pAbi1 after treatment with 10 μM STI571 (IV). Cell attachment was significantly reduced after treatment with STI571 (V). DMSO, dimethyl sulfoxide. Scale
bars as indicated. ***p < 0.001.
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(Figure 3B and C; p < 0.001).Effect of tyrosine kinase inhibition on Abi1
phosphorylation, matrix metalloproteinase 9 secretion
and tumour cell invasion
To confirm inhibition of Abi1 Y435-phosphorylation as
well as specificity of STI571, we performed western im-
munoblotting after treatment with DMSO control or
STI571. The band for phosphorylated Abi1 that was ob-
served under control conditions was extinct after treatment
with 5 and 10 μM STI571, while total Abi1 was strongly
expressed (Figure 4A and Additional file 1: Figure S3A).
There was no decrease, but a slight increase in Erk1/2 ex-
pression and phosphorylation, while protein levels of cleaved
caspase-3 (CC-3) were barely detectable upon treatment
with 5 and 10 μM STI571 (Figure 4A); application of 50 μM
STI571 led to a strong increase in CC-3 expression
(Additional file 1: Figure S3B). Beta-actin was used as
a loading control.Changes in matrix metalloproteinase 9 (MMP-9) se-
cretion were assessed using ELISA (Figure 4B) in cell
culture supernatant from CHD1 cells that had been
treated with STI571 or DMSO control as indicated.
There was a slight decrease in MMP-9 secretion that
was not statistically significant (p = 0.162).
The ability of CHD1 cells to invade through a reconsti-
tuted basement membrane under increasing concentra-
tions of STI571 was investigated applying the ECMatrix
Cell Invasion Assay (EMD Millipore, Darmstadt, GER).
Invaded cells were spun on a glass slide, counterstained
with DAPI and counted automatically. 10 μM of STI571
reduced the invasive potential of CHD1 cells up to 80%
(Figure 4C; p < 0.05).Discussion
Abelson interactor 1 (Abi1), a 65kD substrate of the
eponymous Abelson tyrosine kinase (c-Abl), has been ini-
tially described as a regulator of actin dynamics and syn-
aptic maturation in neurons [7,8,28]. In recent studies,
Figure 3 Gelatine-based ECM degradation assay. A, CHD1 cells seeded on Cy3-conjugated gelatine matrix show cytoplasmic and peripheral positivity
for Cortactin (I) and Abi1 (II) at the sites of matrix degradation. This is confirmed in 3D surface reconstruction for Abi1 (III, arrow). Application of 10 μM STI 571
leads to loss of Abi1 staining in cell periphery together with lack of gelatine degradation (IV). B and C, Application of STI571 in a concentration of
10 μM (I: DMSO control, II: STI571) as well as Abi1 RNAi knockdown (III: pSuper vector control, IV: Abi1 RNAi) inhibits ECM degradation as
shown by a significant reduction in degradation coefficient. DMSO, dimethyl sulfoxide. Scale bars as indicated. ***p < 0.001.
Figure 4 Functional role of Abi1 phosphorylation in MMP-9 secretion and CRC cell invasion. A, western immunoblotting of CHD1 cell lysate
after control (DMSO) treatment or application of STI571 as indicated confirms inhibition of Abi1 Y435-phosphorylation through STI571, while levels of
total Abi1, phospho-Erk1/2 and total Erk1/2 slightly increase upon STI treatment. Levels of cleaved caspase-3 are barely detectable. B, MMP-9 ELISA
from cell culture supernatant after control (DMSO) treatment or application of STI571 shows a non-significant decrease in MMP-9 secretion after treatment
with 5-50 μM STI571. C, increasing concentrations of STI571 inhibit CHD1 CRC cell invasion through reconstituted basement membrane in a dose-dependent
manner. Representative microphotographs (right) show DAPI-counterstained cells that invaded through the sealed pores and were harvested from the lower
chamber. DMSO, dimethyl sulfoxide; MMP-9, matrix metalloproteinase 9; n.s., not significant. *p < 0.05.
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metastatic potential in breast and ovarian cancer, and
several studies described an inhibitory effect of low
concentrations of the c-Abl inhibitor STI571 on colo-
rectal carcinoma cell invasion [18,20,21,29,30]. Our own
group found overexpression of Abi1 in KRAS-mutated co-
lonic precursor lesions and during colon carcinogenesis
[22]; therefore, the aim of this study was to evaluate the
expression and functional role of Abi1 in colorectal cancer
(CRC) invasion as a prerequisite to tumour cell invasion
and metastasis.
Gene expression levels were assessed using data from
545 tissue samples from the GeneSapiens in silico data-
base [31] and showed no significant differences in Abi1
gene expression among adenocarcinomas of gastrointes-
tinal origin. This finding is consistent with protein ex-
pression data obtained from the human protein atlas
[32], another in silico database for tissue microarray-
based protein expression patterns [33,34]. In that data-
base, 86% of gastric and colorectal tumour specimens
showed moderate to strong Abi1 staining intensity with
the identical antibody that was used in the present study.
Taken together, these large-scale expression analyses
confirm the strong expression of Abi1 that we previously
reported for CRC among diverse adenocarcinomas of
the gastrointestinal tract [22]. However, Abi1 mRNA as
well as protein expression data reveals great intra- and
intertumoural heterogeneity. Therefore, we analysed Abi1
expression at the leading edge and in the tumour centre
of 56 invasive CRCs and found that expression of the pro-
tein correlated significantly with infiltrating growth
pattern and high-grade tumour cell budding, both charac-
teristics being widely accepted to be associated with ag-
gressive behaviour and poor prognosis in CRC [2,3]. We
could confirm the correlation between infiltrative growth
and high-grade tumour cell budding as well as lymph or
blood vessel invasion by the tumour in our sample set,
supporting the assumption that these morphologic fea-
tures herald an aggressive tumour phenotype. Lymphatic
and blood vessel invasion, representing significant prog-
nostic variables in CRC, were independently associated
with strong expression of Abi1 at the invasive margin of
the tumours [35]. These findings are consistent with re-
sults obtained from other tumour entities, since it has
been shown that overexpression of Abi1 is associated with
early recurrence and worse survival in breast cancer; in
ovarian cancer, Abi1 is an essential factor in a protein tri-
complex indispensable for metastatic capability of tumour
cells [29,30]. Moreover, immunofluorescence microscopy
revealed a strong staining signal for a phosphorylated iso-
form of Abi1 (Y435) at the leading edge of infiltrating tu-
mours with high expression of Abi1, indicating a role for
Abi1 tyrosine phosphorylation in CRC cell invasion. To
further investigate the functional role of Abi1 in CRC, weanalysed expression and subcellular localization of the
protein in CHD1 cells carrying an activating KRAS G13D
mutation. Initially, the cell line had been selected because
of its high Abi1 expression level [22], but in the present
study, additional immunoblotting experiments showed
cleavage of Laminin5γ2 and loss of E-cadherin expression
in CHD1 cells. Both features are consistent with a pro-
migratory, epithelial-mesenchymal-transition-like cellular
phenotype that might be linked to constitutively active
Ras signalling [36,37]. Accordingly, HDC9 KRAS/BRAF
wild-type colorectal carcinoma cells - that weakly express
Abi1 [22] - display high levels of E-cadherin and no cleav-
age of Laminin5 indicated by a single y2′ band migrating
at 100–105 kD (Additional file 1: Figure S1A).
Immunofluorescence microscopy showed localization
of Abi1 to a peripheral rim around lamellipodia-like
cellular protrusions in cultured CHD1 cells, a distribu-
tion pattern comparable to the established invadopodia
marker Cortactin [4]. The phosphorylated isoform of
Abi1 (Abi1-pY435) was detected in strand-like align-
ments along broad-based cellular protrusions, and both
peripheral staining signals were extinct after treatment
with 10 μM of the Abl kinase inhibitor STI571 (Glivec®).
Furthermore, this treatment prevented CHD1 cells from
firmly attaching to fibronectin-covered surfaces. To verify
the results from IF microscopy, we performed additional
immunoblotting experiments and could confirm that the
band for Y435-phosphorylated Abi1 was extinct after
treatment with STI571, while levels of total Abi1 as well
as total and phosphorylated Erk1/2 were even slightly ele-
vated. These findings support the results from IF staining,
where Abi1 remained strongly expressed upon STI571
treatment, and point towards a cellular redistribution of
Abi1 rather than a decrease in protein expression upon
kinase inhibition. Furthermore, as shown by Erk1/2
phosphorylation, signalling activity along the central
MAPK pathway was not inhibited, but slightly enhanced
by STI571 in the given concentrations. This is consistent
with our previous results showing Abi1 upregulation upon
Ras-MAPK signalling in colorectal precursor lesions, and
might point towards an alternative signalling route via
MAPK upon application of STI [22]. Western immuno-
blotting for cleaved caspase-3 gave no evidence for the
induction of apoptosis upon application of 5 or 10 μM
STI571, while there was strong immunoreactivity upon
50 μM of the drug, consistent with literature data [21].
It has to be recognised, however, while our results do
show a decrease in Abi1 Y435-phosphorylation upon
STI571 especially in the cell periphery that might be
due to c-Abl inhibition, we did not prove that this
tyrosine residue is in fact phosphorylated by c-Abl.
This question should be addressed in further experi-
ments applying knockout of Abl and/or site-directed
mutagenesis.
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related to the architecture observed in lamellipodia, but
they are able to degrade ECM through secretion of lytic
proteinases [4]. When CHD1 cells were seeded upon a
fluorescent gelatine matrix, Abi1 and Cortactin localized
to peripheral foci of matrix degradation, and application
of STI571 as well as RNAi knockdown of Abi1 elimi-
nated the ability of CHD1 cells to lyse the ECM as
shown by a significant decrease in degradation coeffi-
cients. This is consistent with the described role of Abi1
in breast cancer cell invadopodia formation and might
explain the inhibition of colorectal cancer cell migration
and invasion through STI571 that has been previously
shown [16,20]. Therefore, a model where Abi1 and Cor-
tactin act cooperatively in invadopodia at the leading
edge of colorectal carcinoma is quite conceivable; phosphor-
ylated Abi1 would then support local actin reorganization
via activation of nucleation-promoting factors, giving rise to
a branched actin network required for ECM attachment and
invadopodia formation (schematically depicted in Figure 5)
[4,16]. This model is supported by the fact that upregulation
of Abi1-interacting formins and class I NPFs has been re-
ported to be associated with enhanced metastasis in CRC,
and increased MMP9 secretion upon Abi1 overexpression
has been shown in breast cancer [16,25,38]. However, in the
present study, we could not show a significant decrease in
MMP-9 secretion after STI571 treatment, why we concludeFigure 5 A possible pathway for the functional role of Abi1 phospho
Abi1 through Abl or another kinase that is targeted by STI571 enhances ac
invadopodia formation. Secretion of lytic proteinases at the site of invadop
which supports local tumour cell invasion. Abl, Abelson tyrosine kinase; Abi1
homology region; SH3, src homology domain 3; NPF, nucleation-promoting
actin; ECM, extracellular matrix.that the impact of Abi1 phosphorylation seems to lie in
invadopodia formation rather than MMP-9 secretion by
CRC cells. It might be discussed if other proteases play a
central role during tumour cell invasion in CRC. One hint
might be the observed cleavage of Laminin5, since this
process is in most part mediated by MMP-1 and MMP-7,
and only in little part by MMP-9, in colon cancer [36,39]. In
our model, an increase in the local concentration of such
lytic enzymes would lead to ECM dissolution and cleavage
of Laminin5 (schematically depicted in Figure 5); accord-
ingly, associations between high MMP-1 expression levels
and both presence of liver metastases and poor prognosis
have been reported in CRC [40,41].
Finally, we show that tumour cell invasion through a
reconstituted basement membrane was diminished up to
80% after application of 10 μM STI571. These results
are in line with findings from other authors, who de-
scribed a remarkable decrease in cell migration capacity
in response to STI treatment in colon cancer, and indi-
cate that the antiinvasive function of STI571 might at
least in part be mediated by inhibition of Abi1 phos-
phorylation that impairs invadopodia formation by CRC
cells [18,20,21].
Conclusions
Our results show for the first time that Abi1 is overex-
pressed at the invasive edge of colorectal carcinomasrylation in colorectal carcinoma invasion. Y435-Phosphorylation of
tivity of class I and/or class II NPFs, thus facilitating actin branching and
odia formation leads to ECM degradation and cleavage of Laminin5,
, Abelson interactor 1; WAB, Wave-binding domain; HHR, homeobox
factor; Arp2/3, actin-related protein complex; F-actin, filamentous
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phorylated Abi1 as well as Cortactin localize to foci of
matrix degradation in the tumour cell periphery, while
treatment with STI571 leads to a depletion of Y435-
phosphorylated Abi1 in this compartment and suppresses
tumour cell attachment to fibronectin as well as ECM
degradation and tumour cell invasion in vitro. Finally, our
findings support previously published data indicating that
STI571 might be a pharmacological option to prevent the
gain of an invasive phenotype in colorectal cancer.Materials and methods
GeneSapiens database
To evaluate Abi1 gene expression patterns among differ-
ent adenocarcinomas of the gastrointestinal tract, we ob-
tained publicly available expression data for oesophageal
(n = 13), gastric (n = 21), small intestine (n = 6) and
colorectal (n = 505) adenocarcinomas from the GeneSa-
piens database [31,42]. This database contains data from
5 Affymetrix array generations (about 10 000 samples,
average of 11 500 genes per sample) subdivided into
healthy, malignant, and non-tumour disease tissue.Patient samples, clinical data and ethics statement
All patient samples have been submitted to the Institute of
Pathology, Bundeswehrkrankenhaus Ulm, for routine diag-
nostic purposes between 2006 and 2012. Clinic-pathological
data including TNM/UICC stages, tumour differentiation,
infiltration patterns and presence of blood vessel invasion
was obtained from the pathology report archive of the Insti-
tute of Pathology, Bundeswehrkrankenhaus Ulm, and are
summarized in Table 1. All samples have been anonymised
thoroughly for the use in the study. This study has been ap-
proved by the local ethics committee of the University of
Ulm (No. 162/13).KRAS/BRAF mutation testing and MMR protein
immunohistochemistry
Mutation status of KRAS (codons 12, 13 and 61) and
BRAF (codon 600) was performed using KRAS/BRAF
strip assays (Vienna Labs, Vienna, AUT and AID diag-
nostics, Strassberg, GER) as previously described [22].
Shortly, DNA was extracted from 30 mm-thick slides
that were cut off paraffin blocks, xylene treated and
ethanol washed. PCR amplification of KRAS and BRAF
with biotinylated primers and hybridization-based muta-
tion analysis was done according to the manufacturers’
protocols. Immunohistochemistry for mismatch repair
(MMR) proteins MLH-1, MSH-2, MLH-6 and PMS-2
was performed on BenchMark Autostainer (Ventana,
Tucson, USA) using prediluted mouse monoclonal anti-
bodies (Ventana, Tucson, USA).Evaluation of invasion patterns and immunohistochemical
analysis
Invasion pattern of each tumour was assessed applying the
Jass classification modified by Ueno et al., since this scheme
has been shown to represent a good index to estimate the
aggressiveness of colorectal adenocarcinoma [2,3]. The clas-
sification scheme divides invasive margins into “expanding”
(pushing/well circumscribed) or “infiltrating” (diffuse, wide-
spread penetration) and takes into account the grade of
tumour “budding”. As in the original publication, budding
was defined as isolated cells or clusters of less than five can-
cer cells; the number of budding foci was counted in a field
where budding intensity was considered maximal using
a ×25 objective lens. 0–9 foci were defined as low-grade,
while ≥10 foci were defined as high-grade tumour budding.
Abi1 immunohistochemistry was performed on 1–2
slides that displayed the invasive margin of the tumours
using a mouse monoclonal antibody (clone 1B9, MBL,
Woburn, USA; conc. 1:200). Staining intensity was eval-
uated at the invasion front of the tumours using the
scoring system described by Carpenter et al. [23]. The
intensity of immunostaining was graded as negative = 0,
weak = 1, moderate = 2 or strong = 3. The proportion
of positively stained cells was assessed as no cells = 0,
1–25% of cells = 1, 26–50% = 2, 51–75% = 3 and 76–
100% = 4. The numbers representing intensity and per-
centage of stained cells were added together and the
result will be referred to as score.
Cell culture, pharmacological treatment, MMP-9 ELISA
and immunoblotting
CHD1 cells were obtained from the Institute of Path-
ology, University of Ulm, and have been previously pub-
lished [22,43]. Cells were kept under sterile conditions
in RPMI-1640 medium supplemented with 10% FCS.
STI571 was dissolved in DMSO and applied in the indi-
cated concentrations 24 or 48 h prior to cell lysis/fix-
ation. Cell culture supernatants were collected and
delivered to matrix-metalloproteinase 9 ELISA using the
Human MMP-9 Quantikine ELISA Kit (R&D Systems,
Wiesbaden, Germany) while adherent cells were lysed in
standard lysis buffer containing protease and phosphat-
ase inhibitors (Cell Signaling Tech., Boston, USA). Im-
munoblotting was performed according to standard
methods using the following antibodies: mouse mono-
clonal to Abi1 (1:200), MBL, Woburn, USA; mouse
monoclonal to hnRNP K (1:500), Sigma-Aldrich, St.
Louis, USA; rabbit polyclonal to E-Cadherin (1:250),
Sigma-Aldrich, St. Louis, USA; rabbit polyclonal to
Laminin5γ2 (1:250), Sigma-Aldrich, St. Louis, USA; rabbit
monoclonal to Abi1-pY435 (1:250), Abcam, Cambridge,
UK; rabbit monoclonal to p44/42 (Erk1/2, 1:1000),
phospho-p44/42 (phospho-Erk1/2, 1:2000) and cleaved
caspase-3 (1:1000), all from Cell Signaling Tech., Boston,
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Immunofluorescence (IF) staining and fibronectin
adhesion assay
For immunofluorescence (IF) staining’s, CHD1 colorec-
tal carcinoma cells were seeded onto 4-well chamber
slides (Nunc, Wiesbaden, GER), and staining was carried
out as previously described [44]. In short, cells were
fixed in ice-cold 4% paraformaldehyde, permeabilised
with 0.2% Triton-X 100 and incubated with 5% FCS in
PBS. Alternatively, FFPE slides from tumour centre and
invasive margin were deparaffinised, permeabilised and
blocked with 5% FCS in PBS. Afterwards, slides were in-
cubated with one or two of the following primary anti-
bodies for 1 h at room temperature: mouse monoclonal
to Abi1 (1:200, MBL, Woburn, USA); rabbit monoclonal
to Cortactin (1:250, Sigma-Aldrich, St. Louis, USA); rabbit
polyclonal to Abi1-pY435 (1:250, Abcam, Cambridge,
UK); mouse monoclonal to hnRNP K (1:250), Sigma-
Aldrich, St. Louis, USA; rabbit polyclonal to E-Cadherin
(1:250), Sigma-Aldrich, St. Louis, USA; rabbit polyclonal
to Laminin5γ2 (1:250), Sigma-Aldrich, St. Louis, USA.
After washing, slides were incubated with secondary
antibodies (goat polyclonal anti-mouse, Texas Red-
conjugated, Abcam, Cambridge, UK; goat polyclonal
anti-rabbit, DyLight®488- conjugated, Vector Labora-
tories, Burlingame, USA; goat polyclonal anti-mouse
IgM Antibody, Cy2-conjugated, Biozol, Eching, GER;
goat polyclonal anti-mouse IgG (H + L), F(ab’)2 Fragment,
Alexa Fluor® 488-conjugate, Life technologies, Darmstadt,
GER). For phalloidin staining, FITC/ TexasRed-coupled
Phalloidin (Life technologies, Darmstadt, GER) was added
after 30 min incubation at RT in the dark. Slides were
mounted in Vectashield aqueous mounting medium con-
taining DAPI (Vector Laboratories, Burlingame, USA).
For the fibronectin adhesion assay, chamber slides were
covered with Human Plasma Fibronectin (Life technolo-
gies, Darmstadt, GER, conc. 25 μg/ml) for 2 h at 37°C.
Cells were seeded in serum-free medium with either
10 μM STI571 or DMSO (control). 6 hours after seeding,
slides were 6 times rinsed with PBS, and attached cells
underwent fixation and immunofluorescence staining as
described above. Image acquisition as well as quantifica-
tion of IF staining intensities was performed using a Zeiss
Axioplan microscope and Isis software (MetaSystems,
Altlussheim, GER); for fibronectin adhesion assays, quan-
tification of attached cells in 12 visual fields (×10 objective
lens) was done using Image J image analysis software (Na-
tional Institutes of Health, Bethesda, USA).
ECM degradation assay
For visualization of ECM degradation, the QCM™ Gel-
atine Invadopodia Assay (EMD Millipore, Darmstadt,GER) was applied according to the manufacturer’s protocol.
Briefly, 8-well-chamberslides (Nunc, Wiesbaden, GER) were
covered with Poly-L-Lysine, Glutaraldehyde and Cy3-labeled
fluorescent gelatine. CHD1 colorectal carcinoma cells were
seeded in fresh growth medium at 500 μL/well and allowed
to attach for 6 h before RNAi transfection/pharmacological
treatment. After another 36 h (transfection)/24 h (treat-
ment), medium was removed and slides were fixed in 4%
PFA for immunofluorescence staining as described above.
Qualitative and quantitative image analysis was done using
Image J image analysis software (National Institutes of
Health, Bethesda, USA) [45]. 3D surface plots were gener-
ated using the 3D surface plot add-in for Image J (Kai
Uwe Bartel, HTW Berlin, GER). Quantification of extra-
cellular matrix degradation was done using ImageJ ana-
lysis software as previously described [46]. High threshold
was set for the DAPI channel and counted as “particles”
for total cell count and the Cy2/Alexa488/FITC signal for
total cell surface area per field of view. Conversely, low in-
tensity threshold was set for diminished Cy3-gelatin signal
to enable quantification of total degradation area. The ra-
tio between degradation area and cell area was defined as
the degradation coefficient (DC). For quantification of
matrix degradation after RNAi knockdown and pSuper
vector control, only the degradation coefficient of cells
that showed cytoplasmic pSuper marker fluorescence was
calculated. For DMSO- or STI571-treated cells, Phalloidin
counterstaining was used to visualize cell surface area.
Small interference RNA (RNAi) experiments
Knockdown of Abi1 was achieved by RNAi according to
published methods using the pSuper vector (OligoEngine,
Seattle, USA). Complementary oligonucleotides were
annealed and inserted into the Hind III/Bgl II sites of
the pSUPER vector. Initially, the Abi1 construct had
been designed complementary to rattus norvegicus Abi1
mRNA [GenBank NM_024397]. NCBI blast sequence
analysis revealed 100% homology with homo sapiens
Abi1 over a span of 16 nucleotides (sequence in italics), a
feature which has been previously reported to be an even
more effective trigger of RNA induced silencing complex
(RISC) formation than 19-nt-long cores [47]; Abi1 RNAi:
5′-GAT CCC CAG GCT ACA GAC AAG AGG AAT
TCA AGA GAT TCC TCT TGT CTG TAG CCT TTT
TTG GAA A-3′ (sense) and 5′- AGC TTT TCC AAA
AAA GGC TAC AGA CAA GAG GAA TCT CTT GAA
TTC CTC TTG TCT GTA GCC TGG G-3′ (anti-
sense). Protein knockdown efficacy of the construct
in human CHD1 cells was tested using immunofluor-
escence analysis and western immunoblotting (Additional
file 1: Figure S2A and B). Transfections were performed
using the Optifect transfection reagent (Qiagen, Hilden,
GER) according to the manufacturer’s protocol in serum-
free medium (4 μl per μg DNA).
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To evaluate ability of colorectal carcinoma cells to invade
into ECM, cells were seeded onto the polycarbonate mem-
branes of cell culture inserts with 8 μm-pores sealed with
ECMatrix, a reconstituted basement membrane matrix de-
rived from Engelbreth Holm-Swarm (EHS) mouse tumour
(ECMatrix Cell Invasion Assay, EMD Millipore, Darmstadt,
GER) [48]. Cells were then treated with STI571 in the indi-
cated concentrations for 48 hrs; for each treatment, n = 6
experiments were performed. Invasive tumour cells that
have invaded through the ECM-covered pores along an
FCS gradient to the bottom of the polycarbonate mem-
brane and into the outer chamber and were trypsinised,
spun on glass slides (Menzel, Braunschweig, GER) and
counterstained with DAPI. Quantification of cells in 6 vis-
ual fields (×10 objective lens) was done using Image J
image analysis software (National Institutes of Health,
Bethesda, USA).
Statistics
Differences in Abi1 IHC scores between invasion front/
tumour centre, tumours with different invasion patterns
(expanding/low-grade budding, expanding/high-grade bud-
ding, infiltrating/low-grade budding and infiltrating/
high-grade budding) and tumours with and without
lymphovascular infiltration were analysed using the Kruskal-
Wallis test followed by Dunn’s multiple comparison post-
test (SigmaPlot 12.0, Systat Software, Erkrath, Germany).
For quantification of ECM degradation, mean degradation
coefficients for 10–15 visual fields for each treatment/trans-
fection were calculated. The differences between degrad-
ation coefficients after DMSO control/STI571 treatments
and vector control/RNAi knockdown as well as between
numbers of attached/invading cells in fibronectin adhesion/
ECMatrix cell invasion assay were tested for significance
performing nonparametric ANOVA (Kruskal-Wallis) test
using SigmaPlot 12.0 (Systat Software, Erkrath, Germany)
with Dunn’s multiple comparison post-test, where applic-
able. P values <0.05 were regarded as statistically significant.
Consent
All cases that are reported in the manuscript were collected
for histologic examination and diagnosis purpose and thor-
oughly anonymized for the use in this study. Informed con-
sent was therefore not needed to be obtained. This study
was approved by the instutional ethics committee of the
University of Ulm (decision no. 162/13) and conforms to
the current guidelines of the German Ethics Council.
Additional file
Additional file 1: Figure S1. Further analysis of Laminin5, E-cadherin
and hnRNP K expression in CHD1 and HDC9 cells. A, western immunoblottig
against Laminin5 (left), blots are shown after short (15 s) and long exposure(10 min) and E-Cadherin (right). B, immunofluorescence stainings of hnRNP
K/Phalloidin, Laminin5/Phalloidin and E-cadherin/Phalloidin. Scale bars as
indicated. Figure S2. Verification of Abi1 RNAi knockdown in CHD1
CRC colorectal carcinoma cells. A, by immunofluorescence microscopy.
B, by western immunoblotting (compared to pSuper vector control).
Scale bars as indicated. Figure S3. Western immunoblotting of CHD1
cells after application of DMSO control as well as 5, 10 (A) and 50 μM
STI571 (B). A, with antibodies against Abi1 and β-Actin (loading control).
B, with an antibody against cleaved caspase-3 (CC-3). While CC-3 is
barely detectable after DMSO or after application of 5 or 10 μM STI,
there is strong immunoreactivity upon 50 μM STI571. DMSO, dimethyl
sulfoxide.
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